Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc

REGN
Healthcare|Biotechnology|USA
$763.04
+1.19 (+0.16%)
DCF (FCF)
$641.30
Tangible Book
$283.77
Graham Number
$532.32
Earnings Power
$496.16

Upcoming Data Readouts (91)

Sep 2026
Est. completion
P4Eosinophilic Esophagitis (EoE)
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
NCT06665971n=30
Sep 2026
Est. completion
Prurigo Nodularis
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323n=100
Oct 2026
Est. completion
P3Atopic Dermatitis
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)
NCT02612454n=880
Nov 2026
Est. completion
P2Asthma, Allergic
Dupilumab Effects Against Aeroallergen Challenge
NCT05720325n=88
Nov 2026
Est. completion
P2Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086n=120
Dec 2026
Est. completion
P3Chronic Obstructive Pulmonary Disease
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306n=700
Dec 2026
Est. completion
P2Carcinoma, Non-Small-Cell Lung
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
NCT06623656n=112
Dec 2026
Est. completion
P4Atopic Dermatitis
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107n=30
Dec 2026
Est. completion
P1Healthy Volunteers With Hyperlipidemia
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
NCT06452771n=59
Dec 2026
Est. completion
P2Asthma
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
NCT05347771n=240
Dec 2026
Est. completion
P4Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228n=250
Jan 2027
Est. completion
P4Asthma
Investigating Dupilumab's Effect in Asthma by Genotype
NCT03694158n=150
Jan 2027
Est. completion
P1Advanced Solid Tumor
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
NCT05259709n=50
Jan 2027
Est. completion
P3Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360n=210
Jan 2027
Est. completion
P3Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347n=210
Jan 2027
Est. completion
Adverse Pregnancy Outcomes
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
NCT03936335n=3,930
Feb 2027
Est. completion
P2Atrial Fibrillation (AF)
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
NCT07175428n=1,200
Mar 2027
Est. completion
P3Melanoma
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916n=560
Mar 2027
Est. completion
Chronic Rhinosinusitis With Nasal Polyposis
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
NCT04959448n=717
Mar 2027
Est. completion
P1P2Ovarian Cancer
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
NCT04590326n=612

Awaiting Results (20)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
P2
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps
NCT06691113
Jul 2026
P1
Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults
NCT06669234
Jul 2026
P2
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03888105
Jul 2026
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
NCT04550962
Jun 2026
P2
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
NCT06299111
May 2026
P1
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
NCT02651662
May 2026
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
NCT05568459
Apr 2026
Registry of Asthma Patients Initiating DUPIXENT®
NCT04287621
Apr 2026
P2
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441
Apr 2026
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
NCT06099704

Recent Press Releases